NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Scilex Holding Co. SCLX
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$30.3M
▼ 46.5% vs FY2024
EPS · FY25
$-36.48
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-1236.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 30.3M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 1236 cents on every revenue dollar this year.
Per share
USD -36.48
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-1143.7%
Net margin-1236.4%
Return on assets-163.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−7.3%
+5.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 365.0M
total assets, end of FY2025
Total assetsUSD 365.0M
EquityUSD -207.8M
CashUSD 5.0M
Gross debtUSD 83.3M
Net debtUSD 78.3M
Current ratio0.08×
Net debt stands at -38% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.3
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.3
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.4
−0.1
−0.1
−0.0
−0.1
−0.0
EPS, diluted $
−36.48
−8.05
−1.28
−0.17
−0.67
−0.36
Dividend / sh $
·
·
·
·
·
·
Payout %
·
−12
−8
·
·
·
ROE %
·
·
·
·
·
−253786.6
Shares out B
0.01
0.01
0.10
0.14
0.13
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 20
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed